Possibilities of the biologically active complex of phytopreparations in the correction of menopausal disorders

Yashchuk A.G., Dautova L.A., Shaikhutdinova O.V., Muslimova L.R., Berg P.A., Berg E.A., Nasyrova S.F., Kizko I.A., Nazyrova A.G.

1) Bashkir State Medical University, Ministry of Health of Russia, Ufa, Russia; 2) City Clinical Hospital No. 5, Ufa, Russia; 3) Anti-aging Medical Clinic GeN, Ufa, Russia

Objective: To conduct a comparative assessment of the effectiveness of a biologically active complex of phytopreparations and menopausal hormone therapy (MHT) in the treatment of the climacteric syndrome (CS). 
Materials and methods: This was a prospective analysis of the effectiveness of using the biologically active complex of phytopreparations NOW Menopause Support 560 mg and MHT in the treatment of CS in women 6 months after receiving therapy. Group 1 included 50 women with CS who received a phytopreparation made on the basis of soy isoflavonoids, cimicifuga rhizome, and red clover isoflavones. Group 2 included 42 patients who received systemic MHT.
Results: According to the Greene Climacteric Scale, the emotional state significantly improved (10.0 (8.0; 14.0) scores) in the group receiving systemic MHT after 6 months from the beginning of therapy, but it was worse than in the other group (p=0.044). The somatic condition effectively improved in the group receiving MHT (3.0 (3.0; 6.0) scores), however it was not different from the condition of women in the group receiving phytopreparations after 6 months of therapy (3.0 (3.0; 6.0) scores), p=0.233. Vasomotor symptom status significantly improved (p<0.001) in both groups after 6 months of treatment. It was assessed as 3.0 (2.0; 5.0) scores in the group of patients after taking MHT and it differed from the group receiving phytopreparations which was 1.0 (1.0; 3.0) scores (p=0.032); it was associated with the presence of milder forms of vasomotor manifestations of CS in the group receiving phytopreparations.
Conclusion: The treatment of CS with phytopreparations and systemic MHT showed high effectiveness. The phytopreparation made on the basis of soy isoflavonoids, cimicifuga rhizome, red clover isoflavone shows positive results in the treatment of the whole spectrum of menopausal disorders, but it can be used with greater benefit for women with moderate severity of symptoms, where the dominant symptoms are somatic and emotional manifestations.

Authors’ contributions: Yashchuk A.G. – development of the study concept, editing the text, approval of the final version of the article; Dautova L.A. – development of the study design, collecting the material, approval of the final version of the article; Shaikhutdinova O.V., Muslimova L.R., Nasyrova S.F., Kizko I.A., Nazyrova A.G. – collecting the material, editing the text; Berg P.A. – writing the article, statistical processing of the data, collecting the material; Berg E.A. – collecting the material, statistical processing of the data, editing the text.
Conflicts of interest: The authors declare no possible conflicts of interest.
Funding: The study was conducted without sponsorship.
Ethical Approval: The study was approved by the Ethical Review Board of the Bashkir State Medical University, Ministry of Health of Russia.
Patient Consent for Publication: The patients provided an informed consent for the publication of their data.
Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Yashchuk A.G., Dautova L.A., Shaikhutdinova O.V., Muslimova L.R., Berg P.A., Berg E.A., Nasyrova S.F., Kizko I.A., Nazyrova A.G. Possibilities of the biologically active complex of phytopreparations in the correction of menopausal disorders.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2024; (6): 124-132 (in Russian)
https://dx.doi.org/10.18565/aig.2024.127

Keywords

phytoestrogens
menopause
menopausal hormone therapy
menopausal syndrome

References

  1. Marjoribanks J., Farquhar C., Roberts H., Lethaby A., Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 2017; 1(1): CD004143. https://dx.doi.org/10.1002/14651858.CD004143.pub5.
  2. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2018; 25(11): 1362-87. https://dx.doi.org/ 10.1097/GME.0000000000001241.
  3. Chaikittisilpa S., Soimongkol K., Jaisamrarn U. Efficacy of oral estrogen plus testosterone gel to improve sexual function in postmenopausal women. Climacteric. 2019; 22(5): 460-5. https://dx.doi.org/10.1080/13697137.2019.1577378.
  4. Morga A., Ajmera M., Gao E., Patterson-Lomba O., Zhao A., Mancuso S. et al. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause. Menopause. 2024; 31(1): 68-76. https://dx.doi.org/10.1097/GME.0000000000002281.
  5. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50. https://dx.doi.org/10.3109/13697137.2015.1129166.
  6. Monteleone P., Mascagni G., Giannini A., Genazzani A.R., Simoncini T. Symptoms of menopause - global prevalence, physiology and implications. Nat. Rev. Endocrinol. 2018; 14(4): 199-215. https://dx.doi.org/10.1038/nrendo.2017.180.
  7. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2021. [Ministry of Health of the Russian Federation. Clinical guidelines. Menopause and climacteric state in women. 2021.(in Russian)].
  8. Kanadys W., Barańska A., Błaszczuk A., Polz-Dacewicz M., Drop B., Kanecki K. et al. Evaluation of clinical meaningfulness of red clover (Trifolium pratense L.) extract to relieve hot flushes and menopausal symptoms in peri- and post-menopausal women: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2021; 13(4): 1258. https://dx.doi.org/10.3390/nu13041258.
  9. Handley A.P., Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J. Am. Assoc. Nurse Pract. 2015; 27(1): 54-61. https://dx.doi.org/10.1002/2327-6924.12137.
  10. Sarri G., Pedder H., Dias S., Guo Y., Lumsden M.A. Vasomotor symptoms resulting from natural menopause: a systematic review and network meta-analysis of treatment effects from the National Institute for Health and Care Excellence guideline on menopause. BJOG. 2017; 124(10): 1514-23. https://dx.doi.org/10.1111/1471-0528.14619.
  11. Castelo-Branco C., Gambacciani M., Cano A., Minkin M.J., Rachoń D., Ruan X. et al. Review & meta-analysis: isopropanolic black cohosh extract iCR for menopausal symptoms - an update on the evidence. Climacteric. 2021; 24(2): 109-19. https://dx.doi.org/10.1080/13697137.2020.1820477.
  12. Рафаэлян И.В., Балан В.Е., Ковалева Л.А. Эффективность и безопасность применения экстракта цимицифуги рацемозы в терапии климактерического синдрома в течение года (результаты собственного исследования). Медицинский совет. 2014; (7): 54-7. [Rafaelyan I., Balan V., Kovaleva L. Efficacy and safety of Cimicifuga racemosa in management of climacteric syndrome during a year (results of own study). Medical Council. 2014; (7): 54-7. (in Russian)]. https://dx.doi.org/10.21518/2079-701X-2014-7-54-57.
  13. Прилепская В.Н., Ледина А.В. Биоактивные компоненты растений и лечение климактерического синдрома. Акушерство и гинекология. 2011; 7-1: 101-8. [Prilepskaya V.N., Ledina A.V. Bioactive components of plants and treatment for menopausal syndrome. Obstetrics and Gynecology. 2011; (7-1): 101-8. (in Russian)].
  14. Сerqueira R.O., Frey B.N., Leclerc E., Brietzke E. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch. Womens Ment. Health. 2017; 20(6): 713-9. https://dx.doi.org/10.1007/s00737-017-0791-0.
  15. Verkaik S., Kamperman A.M., van Westrhenen R., Schulte P.F.J. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2017; 217(2): 150-6. https://dx.doi.org/10.1016/j.ajog.2017.02.028.
  16. Kenda M., Glavač N.K., Nagy M., Sollner Dolenc M., On Behalf Of The Oemonom. Herbal products used in menopause and for gynecological disorders. Molecules. 2021; 26(24): 7421. https://dx.doi.org/10.3390/molecules26247421.
  17. Puglia L.T., Lowry J., Tamagno G. Vitex agnus castus effects on hyperprolactinaemia. Front. Endocrinol. (Lausanne). 2023; 14: 1269781. https://dx.doi.org/10.3389/fendo.2023.1269781.
  18. Seyedabadi S., Hoseini Z.S., Ferns G.A., Bahrami A. Effects of curcumin supplementation on insomnia and daytime sleepiness in young women with premenstrual syndrome and dysmenorrhea: A randomized clinical trial. Avicenna J. Phytomed. 2023; 13(6): 585-96. https://dx.doi.org/10.22038/AJP.2023.21916.

Received 27.05.2024

Accepted 11.06.2024

About the Authors

Alfiya G. Yashchuk, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology No. 2, Bashkir State Medical University, Ministry of Health of Russia, 450008, Russia, Ufa, Lenin str., 3, +73472649650, alfiya_galimovna@mail.ru, https://orcid.org/0000-0003-2645-1662
Liliana A. Dautova, PhD, Associate Professor at the Department of Obstetrics and Gynecology No. 2, Bashkir State Medical University, Ministry of Health of Russia,
450008, Russia, Ufa, Lenin str., 3, +79177556262, lili.d5@yandex.ru, https://orcid.org/0000-0002-8281-5515
Olga V. Shaikhutdinova, obstetrician-gynecologist, Chief Physician, City Clinical Hospital No. 5, 450005, Russia, Ufa, Parkhomenko str., 93, +73472649650, p.a.berg@mail.ru, https://orcid.org/0009-0009-2721-4440
Leisan R. Muslimova, Head of Antenatal Clinic, City Clinical Hospital No. 5 450005, Russia, Ufa, Parkhomenko str., 93, +73472649650, p.a.berg@mail.ru,
https://orcid.org/0009-0009-2782-541X
Polina A. Berg, Teaching Assistant, Department of Obstetrics and Gynecology No. 2, Bashkir State Medical University, Ministry of Health of Russia, 450008, Russia, Ufa,
Lenin str., 3, +79373203818, p.a.berg@mail.ru, https://orcid.org/0000-0001-5266-0412
Edvard A. Berg, PhD, Associate Professor at the Department of Obstetrics and Gynecology No. 2, Bashkir State Medical University, Ministry of Health of Russia,
450008, Russia, Ufa, Lenin str., 3, +79273379003, nucleardeer@gmail.com; https://orcid.org/0000-0002-2028-7796
Svetlana F. Nasyrova, PhD, Associate Professor at the Department of Obstetrics and Gynecology No. 2, Bashkir State Medical University, Ministry of Health of Russia, 450008, Russia, Ufa, Lenin str., 3, +79196154652, ufa863@mail.ru, https://orcid.org/0000-0002-2313-7232
Irina A. Kizko, obstetrician-gynecologist, Chief Physician, Anti-aging Medical Clinic GeN, 450006, Russia, Ufa, Krasnodonskaya str., 3, +79373203818,
nucleardeer@gmail.com, https://orcid.org/0009-0004-7290-9122
Alsu G. Nazyrova, PhD, obstetrician-gynecologist, Deputy General Director for Medical Issues, Anti-aging Medical Clinic GeN, 450006, Russia, Ufa, Krasnodonskaya str., 3, +79373203818, nucleardeer@gmail.com, https://orcid.org/0009-0000-7129-9298
Corresponding author: Polina A. Berg, p.a.berg@mail.ru

Similar Articles

By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.